Competing to offer a comprehensive genomic profiling service for solid or hematology oncology tumor samples is challenging, especially as panels increase in size and complexity. QIAGEN Clinical Insight (QCI) Interpret One is clinical decision support software integrated with professional variant interpretation services that enables rapid, evidence-based reporting of oncology NGS tests at scale. 

Connected to the world’s most comprehensive, manually curated knowledge base that is updated weekly, QCI Interpret One dynamically computes variant classifications according to AMP/ASCO/CAP and ACMG/AMP guidelines with full transparency. Users get access to over 200,000 pre-formulated, oncologist-reviewed variant interpretation summaries and can build customizable, oncologist-ready reports with the latest diagnostic and prognostic information, as well as biomarker-directed therapies and clinical trials. 

In this webinar, attendees will learn: 

  • How QCI Interpret One computes variant classifications
  • How simple it is to submit variants for professional interpretation via the software
  • How QCI Interpret One eliminates the need for variant curation 
  • How users can generate customizable, oncologist-ready reports according to AMP/ASCO/CAP guidelines for therapeutic, prognostic, and diagnostic actionability

 

About the speaker
Beate Litzenburger, PhD, Global Product Director of Oncology
QIAGEN Digital Insights
Dr. Beate Litzenburger is the Global Product Director of Oncology for Clinical Decision Support Software and Interpretation Services at QIAGEN. Prior to joining the QIAGEN team, Dr. Litzenburger led clinical decision support and the interpretation of patient cases for several next generation sequencing protocols at MD Anderson Cancer Center. In this role, Dr. Litzenburger was responsible for providing alteration interpretation, drug, and clinical trial options to clinicians. Dr. Litzenburger earned her Ph.D. in molecular genetics from the University of Aachen in Germany and was a National Cancer Institute-supported post-doctoral fellow in the Department of Clinical Cancer Prevention at MD Anderson Cancer Center.
Sheryl Elkin, PhD, Chief Scientific Officer
N-of-One, a QIAGEN company
Sheryl Krevsky Elkin, PhD, is the Chief Scientific Officer at N-of-One, a QIAGEN company. An early member of the N-of-One team, Dr. Elkin has led the interpretation of thousands of patient cases, establishing a rigorous process for the analysis of scientific and clinical evidence and presentation of molecular and clinical evidence to physicians to help guide their therapeutic decisions. Dr. Elkin has taken a lead role in the development of the N-of-One clinical interpretation methodology to support clinicians in identifying therapeutic strategies specific to each patient. Prior to joining N-of-One, Dr. Elkin completed her postdoctoral fellowship at the Massachusetts Institute of Technology’s Center for Cancer Research, where she earned a fellowship from the Leukemia and Lymphoma Society. She earned her doctorate in Biological and Biomedical Sciences from Harvard Medical School and an A.B. in Biology and Music from Amherst College, graduating Phi Beta Kappa and summa cum laude, with High Distinction in Biology.
Date of recording:Friday, December 3, 2021
Duration:45 minutes
Categories
Webinar
Human Genetics
Bioinformatics - Clinical Interpretation and Reporting
Bioinformatics
Informatics & Data